Indevus, Endo Face Another Class Action Over Merger
Indevus Pharmaceuticals Inc. is facing another proposed shareholder class action seeking to block a merger with Endo Pharmaceuticals Holdings Inc., claiming Endo's $4.50 a share offer undervalues the specialty drug company....To view the full article, register now.
Already a subscriber? Click here to view full article